NEUROPEPTIDE / NEUROLOGICAL RESEARCH
Selank is a synthetic heptapeptide derived from a fragment related to the naturally occurring peptide tuftsin. It has been investigated for its effects on neurological signaling, stress-response biology, and cognitive processes.
PRIMARY RESEARCH AREAS
Stress-response biology; GABAergic neurotransmission; cognitive processes; neuropeptide signaling; neurological research.
EVIDENCE LEVEL
Limited human evidence; supported primarily by preclinical and mechanistic research.
Selank is a synthetic heptapeptide investigated primarily for its effects on neurological signaling and stress-response biology. Research has examined possible interactions with GABAergic neurotransmission, neuropeptide systems, gene expression, learning, memory, and other cognitive processes. A limited number of human clinical studies have been published, but much of the evidence remains preclinical or mechanistic, and larger independent human trials are lacking.
Selank is a synthetic peptide consisting of seven amino acids and was developed from a short sequence related to tuftsin, a naturally occurring peptide involved in immune signaling. Selank has been investigated primarily for its effects on the central nervous system, with research examining stress-response pathways, neurotransmitter signaling, cognitive processes, and neuropeptide activity. Published studies include both preclinical experiments and a limited number of human clinical investigations. Proposed mechanisms include interactions with GABAergic signaling, gene expression, and endogenous neuropeptide systems, although the precise mechanisms responsible for its observed effects remain under investigation.
Selank emerged from research examining how short regulatory peptides may influence neurological function and the biological response to stress. Researchers have investigated Selank in experimental models of anxiety, learning, memory, neurotransmitter activity, and gene expression, along with a limited number of human clinical studies involving anxiety-related conditions. Particular attention has been given to possible interactions with GABAergic signaling and endogenous neuropeptide systems. Although these findings have generated scientific interest, the evidence base remains relatively small, and many proposed mechanisms have not been established through large, independently replicated human studies.
Selank does not appear to act through a single established molecular target. Experimental research suggests that its biological activity may involve modulation of several interconnected signaling systems within the nervous system. Particular attention has focused on GABAergic neurotransmission, including possible effects on GABA receptor-related signaling, as well as changes in the expression of genes involved in neurotransmission. Research has also examined Selank’s interaction with endogenous neuropeptide systems, including enkephalin metabolism. These mechanisms remain under investigation, and their relative contribution to Selank’s observed biological effects has not been fully established.
Published research on Selank includes preclinical studies examining neurological signaling, gene expression, GABAergic neurotransmission, learning and memory, and endogenous neuropeptide systems. A limited number of human studies have also evaluated Selank in anxiety-related conditions, including comparisons with established anxiolytic medications. While these studies have reported findings of scientific interest, the overall clinical evidence remains limited, and larger independently replicated human trials are lacking.
Selank’s evidence base remains limited. Although published human studies exist, they are relatively small, and much of the clinical literature comes from a limited number of research groups. Large, independently replicated clinical trials are lacking. Proposed mechanisms involving GABAergic signaling, gene expression, and endogenous neuropeptide systems remain under investigation, and it is not yet clear how findings from experimental models translate to broader human outcomes. Long-term safety, pharmacokinetics, and potential interactions also remain insufficiently characterized.
Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38–48. PMID: 18454096.
Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17–22. PMID: 25176261.
Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. PMID: 26924987. DOI: 10.3389/fphar.2016.00031.
Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001;131(4):315–317. PMID: 11550013. DOI: 10.1023/A:1017979514274.
Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017;8:89. PMID: 28293190.
References are selected primary-source publications supporting the principal claims presented in this research profile.
Evidence sources include peer-reviewed human clinical studies, preclinical animal research, cell-based experiments, and mechanistic studies examining GABAergic neurotransmission, gene expression, and endogenous neuropeptide systems. Primary literature was identified through PubMed-indexed publications. Evidence was reviewed through September 2026.
Published Selank research includes laboratory and cell-based studies, animal models, mechanistic investigations, and a small number of human clinical studies. Preclinical work has examined neurotransmitter signaling, gene expression, neuropeptide metabolism, learning, memory, and behavioral responses to stress. Human research has primarily involved relatively small studies evaluating anxiety-related outcomes. Large, independently replicated clinical trials remain absent from the published evidence base.
CELLULAR / IN-VITRO EVIDENCE
Cell-based research has examined how Selank may influence gene expression and neurotransmitter-related signaling. Studies using neuronal cell models have investigated genes associated with GABAergic neurotransmission and other signaling pathways involved in nervous system function. These experiments provide potential clues about Selank’s molecular activity, but findings from isolated cells cannot establish how the compound behaves in a complete living organism or predict clinical effects in humans.
ANIMAL / PRECLINICAL EVIDENCE
Animal studies have examined Selank in models involving stress-related behavior, learning, memory, and neurological signaling. Experimental findings have suggested effects on behavioral responses to stress and on biological systems associated with neurotransmission and endogenous neuropeptide activity. Additional preclinical work has investigated interactions with GABAergic pathways and enkephalin metabolism. These findings help identify potential mechanisms for further study, but results from animal models cannot be assumed to translate directly to humans.
Human research on Selank is limited but includes small clinical studies in anxiety-related conditions. Published studies have compared Selank with established anxiolytic medications and reported reductions in anxiety-related symptoms, with some reports also describing mild cognitive or nootropic effects. However, these studies involved relatively small participant groups, much of the clinical literature originates from a limited number of research teams, and large independently replicated trials are lacking. The existing human evidence is therefore preliminary and should be interpreted cautiously.
Stress-Response Biology: Selank has been studied for its effects on behavioral and neurological responses to stress, with both preclinical and limited human research reporting anxiolytic-related findings.
GABAergic Signaling: Experimental studies suggest Selank may influence pathways associated with GABAergic neurotransmission, including gene-expression changes and possible modulation of GABA-related signaling.
Cognitive Processes: Research has examined Selank in relation to learning, memory, attention, and other cognitive functions, although human evidence for specific cognitive effects remains limited.
Neuropeptide Regulation: Selank has also been studied for potential effects on endogenous peptide systems, including enkephalin metabolism, which may contribute to its broader neurological activity.
Published human studies have generally described Selank as well tolerated within the limited populations studied, with no major safety signals reported in those small trials. However, the available clinical safety data are sparse, and there is not enough evidence to define its long-term safety profile, uncommon adverse effects, interaction risks, or safety across broader populations. Because Selank remains an investigational compound, its overall safety and tolerability profile should be considered incompletely characterized.
Selank is supported by an interesting but still limited body of research. Important gaps include the absence of large, independently replicated clinical trials, limited long-term safety data, incomplete pharmacokinetic characterization, and uncertainty surrounding its precise molecular mechanisms. Much of the mechanistic evidence comes from cellular and animal models, while the available human studies are relatively small and concentrated among a limited number of research groups. Future research would need to clarify dose-response relationships, reproducibility of reported effects, long-term safety, and whether proposed mechanisms such as GABAergic modulation and neuropeptide regulation translate into consistent biological effects in humans.
Editorially Reviewed
LAST REVIEWED
New research profile added September 2026. Reviewed for scientific accuracy, evidence characterization, research limitations, and consistency with The Amino Report editorial standards.